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tein expression correlated with TKTL1 protein expression in 
SW480 spheroids over time. On the one hand, induction of 
hypoxia in T84 spheroids did not induce TKTL1; on the other 
hand, hypoxia by incubation at 1% O 2 in a hypoxia incubator 
chamber clearly showed an upregulation of TKTL1. In 50%
of CRC patients, TKTL1 protein expression was upregulated 
in tumor compared to non-tumor tissue. The immunohisto-
chemical staining of TKTL1 in CRC patient samples resulted 
in 14 positive and 30 negative samples.  Conclusions: TKTL1 
expression correlated with HIF-1α protein expression and 
was induced upon hypoxic conditions which could facilitate 
energy supply to tumors under these circumstances. 
 © 2013 S. Karger AG, Basel 
 Introduction 
 Enhanced glucose consumption in cancer may be due 
to an extended demand of ribose for nucleic acid biosyn-
thesis and subsequently proliferation of tumor cells. A 
 Key Words 
 Colorectal cancer · Aerobic glycolysis · Hypoxia · Pentose 
phosphate way 
 Abstract 
 Background and Aims: Transketolase-like (TKTL) 1 is one of 
the key enzymes for anaerobic sugar degradation even in the 
presence of oxygen (aerobic glycolysis). Transketolase-de-
pendent reactions supply malignant tumors with ribose and 
NADPH. Therefore, TKTL1 activity could be crucial for tumor 
proliferation and survival. The aim of the study was to evalu-
ate the expression of TKTL1 in colorectal cancer (CRC) and its 
regulation under hypoxic conditions.  Methods: We studied 
TKTL1 mRNA and protein expression in CRC cell lines and hu-
man CRC biopsies by quantitative real-time PCR, Western 
blotting and immunohistochemistry. Regulation of TKTL1 
under oxygen depletion was analyzed by cultivating cells ei-
ther in a three-dimensional spheroid model or in a hypoxia 
incubator chamber.  Results: TKTL1 mRNA was heteroge-
neously expressed in monolayers of cells with high levels in 
HT-29 and SW480. TKTL1 protein was also clearly detectable 
in HT-29 and SW480. Hypoxia-inducible factor (HIF)-1α pro-
 Received: May 6, 2013 
 Accepted: August 6, 2013 
 Published online: October 26, 2013 
 Alexandra Cee 
 Division of Gastroenterology and Hepatology 
 Department of Internal Medicine, University Hospital Zurich 
 Sternwartstrasse 14, CH–8091 Zurich (Switzerland) 
 E-Mail alexandra.cee   @   usz.ch 
 © 2013 S. Karger AG, Basel
0012–2823/13/0883–0182$38.00/0 
 www.karger.com/dig 
 S. Bentz and A. Cee contributed equally to this work. 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
, R
eg
en
sb
ur
g
13
2.
19
9.
14
5.
19
5 
- 1
0/
10
/2
01
9 
9:
03
:2
2 
AM
 TKTL1 in Hypoxia and CRC Digestion 2013;88:182–192
DOI: 10.1159/000355015
183
special feature of colorectal cancer (CRC) cells, when 
compared to surrounding ‘normal’ cells, is an 8.5- to 15-
fold enhanced glucose turnover rate  [1] .
 The pentose phosphate pathway (PPP) enables oxy-
gen-independent glucose degradation by transketolases 
and generates, among other things, riboses for nucleic 
acid biosynthesis. In cancer cells, transketolase-like 
(TKTL) 1 protein is observed to be specifically upregu-
lated in comparison to TKT or TKTL2  [2–4] .
 In 1924, Otto Warburg described that cancer cells me-
tabolize glucose to lactate even in the presence of oxygen 
(known as Warburg effect)  [5] . Lactate promotes the ex-
pression of hypoxia-inducible factor 1 (HIF-1) and the 
acidification of the adjacent healthy cells  [6] . The tran-
scription factor HIF-1 represents a key regulator for the 
elevated fermentation of glucose  [7] and is increased 
during colorectal carcinogenesis  [8, 9] . The HIF-1α sub-
unit is tightly regulated at the translational level as well 
as its posttranslational stability. The latter is controlled 
by the oxygen level in the cell. Interestingly, TKTL1 is 
able to stabilize HIF-1α, indicating a tight regulation and 
interaction  [10] . Under conditions of limited oxygen 
supply that are frequently found in tumors, the malig-
nant cells may switch to the nonoxidative part of the PPP. 
This results in a higher supply of ribose, independence of 
mitochondrial energy production as well as indirect gen-
eration of acetyl-CoA for fatty acid and cholesterol pro-
duction  [11] . Furthermore, tumor cells are protected 
against reactive oxygen species via NADPH production 
and tissue acidosis through the production of lactic acid. 
Whereas lactic acid normally mediates cell death via p53, 
tumor cells are often protected by p53 mutations  [4] . 
Moreover, the NADPH production through the PPP 
seems to have a protective effect against oxidative or rad-
ical stress  [12] . In breast cancer specimens, the expres-
sion of Akt  [13] , glucose transporters (GLUT)  [14] and 
TKTL1  [13] was elevated compared to normal tissue. 
This indicates that the enhanced glucose turnover is fu-
eled by an increased glucose uptake through GLUT and 
conversion by TKTL1.
 Additionally, TKTL1 has been qualified as a proto-on-
cogene associated with demethylation of DNA  [15] . This 
is in accordance with a significant overexpression of 
TKTL1 in several different tumors like nasopharyngeal 
 [16] , pulmonary  [17] , thyroid papillary  [18, 19] , gastric 
 [20] , ovarian  [21, 22] , cervical  [23] and metastasizing re-
nal cell carcinoma  [11] . In general, increased TKTL1 ex-
pression correlates with poor patient outcome and tumor 
progression  [20, 23–25] . TKTL1 is an independent prog-
nostic factor for reduced survival of patients with laryn-
geal squamous cell  [11, 26] , urothelial carcinoma  [11] , 
colon carcinoma (CC)  [27] , and nonsmall lung cancer. In 
thyroid papillary carcinoma, there is a correlation be-
tween TKTL1 and the presence of lymph node metastases 
 [4] . In rectum carcinoma, there is a correlation between 
TKTL1 expression and the presence of metastases and re-
currence  [24] . Inhibitors of total transketolase activity or 
gene expression suppressed tumor growth  [16, 28–31] , 
whereas activation led to enhanced tumor growth  [28] . In 
addition, dietary studies indicate that the inhibition of the 
PPP suppresses tumor growth  [32] .
 As CRC cells consume a high amount of glucose and 
TKTL1 plays an important role in its metabolism via the 
PPP in several malignant cells  [11, 20] , we assumed a po-
tential role of TKTL in CRC physiology. However, until 
now only limited data on TKTL1 expression in CRC lines 
and CRC in humans  [33, 34] are available  [35] .
 Therefore, we investigated the expression of TKTL1 in 
11 different CRC cell lines, spheroids and hypoxia cham-
bers as well as patient specimens to elucidate the role of 
TKTL1 and its regulation under hypoxic conditions in 
CRC.
 Methods 
 Cell Culture Conditions 
 Low-passage Caco-2, HT-29, WiDr, LoVo, LS 174T and T84 
were maintained as monolayer in DMEM low or high glucose at 
37   °   C and 10% CO 2 . SW403, SW480, SW620, SW837 and SW948 
were maintained as monolayer in RPMI 1640 at 37  °  C and 5% CO 2 . 
All media were supplemented with 10% fetal calf serum and 50 U 
of penicillin and 50 μg of streptomycin (all from Invitrogen, Ger-
many).
 Hanging Drop Method or Hypoxia Incubator Chamber 
 Cells were cultivated in the hanging drop method (spheroids) 
as described previously  [36] . Five thousand SW480 or T84 cells per 
well were cultivated in 60-well Terasaki plates (Greiner Bio-One, 
Switzerland) for 1–5 days in 23 μl of the corresponding media. Me-
dium was not changed over the 5 days of cultivation.
 Cells were cultivated on transwells for 2 weeks at 21% O 2 to al-
low the cells to form a tight monolayer. After 2 weeks, the medium 
was removed and either medium with or without glucose was ap-
plied. Cells were transferred to a hypoxia incubator chamber (In-
Vivo400, UK) and cultivated at 37  °  C, 5% CO 2 and 1% O 2 . Control 
samples were kept under normal conditions. After 4 h, 1 and 3 
days, cells were harvested and RNA and protein were collected.
 Patient Material – Protein Analysis and 
Immunohistochemistry 
 Twenty surgically resected specimens (10 tumor and matching 
non-tumor) were obtained from the Institute of Surgical Pathol-
ogy of the University Hospital Zurich. The study was approved by 
the local ethical committee (Ethical Committee for Surgery, Anes-
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thesiology and Pathology at the University Hospital Zurich). Each 
participant gave written consent.
 Forty-four patient samples were stained for TKTL1 by immu-
nohistochemistry. Paraffin-fixed sections were rehydrated and 
heated for antigen unmasking in 10 mmol/l of sodium citrate buf-
fer (pH 6.0, Sigma-Aldrich, USA). Peroxidases were inhibited by 
incubating the sections for 10 min in 3% hydrogen peroxide in 
methanol. Slides were blocked with 1% goat serum (Sigma-Al-
drich, USA) in 1× PBS for 15 min and incubated with the mono-
clonal mouse anti-TKTL1 antibody (RIDA ® PentoCheck ® IHC, 
clone 1210-4, R-Biopharm AG, Germany) and a peroxidase-con-
jugated secondary anti-mouse antibody (Santa Cruz Biotechnolo-
gies, USA). Staining was developed by adding 3,3-diaminobenzi-
dine (DAKO, Denmark) with subsequent counterstaining using 
hematoxylin. Afterwards, sections were dehydrated by washing in 
xylene and graded ethanol and embedded in Pertex (Calbiochem, 
Norway). The staining intensity was classified as weak, moderate, 
or strong. The percentage of positively stained tumor cells was as-
sessed semiquantitatively. All negative cases were confirmed by a 
second staining. Staining was scored by the immunoreactive score 
(IRS or Remmele score). The IRS considers the percentage of pos-
itive tumor cells and the staining intensity. Staining intensity  ≥ 2 
and >10% positive stained cells resulted in an IRS of  ≥ 4. Only sam-
ples with an IRS  ≥ 4 were evaluated as positive staining result. For 
clinical correlation, file records of the patients were investigated 
( table 1 ). Cancer stage was evaluated by the tumor node metastases 
(TNM) staging system (6th edition).
 RNA Extraction and Quantitative Real-Time PCR  
 Total RNA was extracted using the RNeasy Mini Kit and the 
automated sample preparation system Qiacube according to manu-
facturer’s instructions (Qiagen, Switzerland). cDNA was synthe-
sized with High-Capacity cDNA Reverse Transcription Kit ac-
cording to the manufacturer’s instructions (Applied Biosystems, 
USA). qRT-PCR was performed under the following cycling con-
ditions: 20 s at 95   °   C, then 45 cycles at 95   °   C for 1 s and 60   °   C for 
20 s with the TaqMan Fast Universal Mastermix and the following 
primers: hTKTL1 sense 5 ′ -CGCCGAGCACTGCATAAAC-3 ′ , 
antisense 5 ′ -CCACATAAGTGTTCCACCCAAA-3 ′ and fluores-
cent probe 6FAM-TCTATCAGAGGCGCTGCGAAGC-MGB 
with nonfluorescent quencher in the 7500 Fast Thermal Cycler. 
Glut1, HkII and ACTB mRNA levels were determined using gene 
expression assays (HKII: Hs00606086_m1; Glut1: Hs00892681_
m1; ACTB: 4310881E) (all from Applied Biosystems, USA). Each 
sample was analyzed in triplicate, and the ΔCt method was applied.
 Protein Extraction and Western Blotting 
 Cells or tissue were resuspended in M-PER lysis buffer (Ther-
mo Fisher Scientific Inc., USA), sonicated, centrifuged for 5 min 
at 13,000  g and the supernatant was further processed. Protein was 
separated on 4–12% Bis-Tris gradient gels with MOPS SDS run-
ning buffer and transferred onto a nitrocellulose membrane (Invi-
trogen, USA). After blocking with 5% milk powder, 3% BSA and 
0.1% Tween 20 (Roth, Germany) in 1× PBS, proteins were labeled 
with primary antibodies (TKTL1: 1: 100 dilution, clone 1210-4, R-
Biopharm, Germany; HIF-1α: 1: 1,000, Novus Biologicals, USA) 
and peroxidase-conjugated secondary goat anti-mouse or goat an-
ti-rabbit antibody (1: 3,000, Santa Cruz, USA). Protein bands were 
visualized using a commercial chemiluminescence detection kit 
(ECL Plus; Amersham Biosciences, USA) according to the manu-
 Table 1. Patient characteristics
ID Gender Age, years G
Patient samples used for Western blotting
G05.89 female 40 2
G05.167 male 60 2
G05.220 male 76 2
G04.258 female 77 2
G05.274 female 43 2
G05.286 female 60 2
G04.541 male 88 2
G04.623 female 84 2
Neuroendocrine carcinoma
G08.148 female 75
Extra-abdominal fibromatosis (desmoid tumor)
G05.586 male 62
Patient samples used for immunohistochemical staining 
1 male 65 2
2 male 74 2
3 male 58 2
4 female 80 2
5 male 76 2
6 female 56 2
7 male 82 3
8 female 88 3
9 female 64 2
10 male 69 3
11 female 78 2
12 male 71 3
13 male 68 2
14 female 90 3
15 male 67 2
16 female 68 2
17 male 65 2
18 male 77 2
19 female 60 2
20 female 65 2
21 female 86 3
22 female 50 2
23 male 70 2
24 female 86 2
25 male 56 2
26 male 85 2
27 male 76 2
28 male 93 2
29 female 87 2
30 male 77 3
31 male 69 2
32 female 56 2
33 female 92 2
34 female 67 3
35 female 53 1
36 male 53 3
37 male 75 2
38 female 69 3
39 female 52 2
40 female 80 3
41 male 77 2
42 male 76 1
42 male 73 2
44 male 60 2
 Classification by the tumor grading system (G) in patients suf-
fering from CRC.
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facturer’s protocol and exposed on a film. Equal loading of the 
samples was demonstrated by reprobing with anti-β-actin (Ms X 
Actin, Chemicon, Switzerland).
 Immunocytochemical Staining  
 Cells were grown in transwell plates and fixed on day 3 in 4% 
PFA in 1× PBS. Cells were permeabilized with 0.3% Triton X 100 
in 1× PBS, blocked with 1% BSA in 1× PBS in a humidified cham-
ber and incubated with the primary anti-human TKTL1 antibody 
(1: 100) at 37  °  C for 1 h, Cy3-labeled anti-mouse antibody as a sec-
ondary antibody (1: 500, Jackson ImmunoResearch, USA) and 
mounted using the Hard Set Mounting Medium (Vector Labora-
tories, USA). 
 Data Analysis and Statistics 
 The level of protein expression in patient samples was quanti-
fied by the OptiQuant analysis software.
 Statistical analysis was carried out using Mann-Whitney test 
with SPSS. Data are shown as mean value ± standard error. Statis-
tical significance was based on a p value <0.05.
 Results 
 TKTL1 mRNA and Protein Expression in vitro 
 TKTL1 mRNA expression was analyzed in 11 cell lines 
by qRT-PCR. All cell lines expressed TKTL1 mRNA ex-
cept WiDr and SW620 ( fig.  1 a). The highest TKTL1 
mRNA expression was observed in HT-29 cells. High 
mRNA expression of TKTL1 was also detected in Caco-2, 
T84, SW480 and SW837 cell lines. All other investigated 
cell lines, namely LoVo, LS 174T, SW403 and SW948, 
showed lower mRNA levels of TKTL1.
 Western blotting was performed in order to demon-
strate the presence of TKTL1 protein. HT-29 and SW480 
cells showed high expression of TKTL1 protein ( fig. 1 b) 
corresponding to the qRT-PCR data ( fig. 1 a). In all other 
9 cell lines, TKTL1 protein was barely detectable.
 For TKTL1 localization within the cells, we performed 
immunocytochemistry in HT-29, SW480 and T84 cells 
( fig. 2 a–f). All three cell lines expressed TKTL1 mainly in 
the cytoplasm ( fig. 2 a–f). To account for a difference in 
expression level by prolonged cultivation time, SW480 
cells were grown over 10 days. No difference in expres-
sion pattern over time was detected (data not shown).
 TKTL1 and HIF-1α Protein Expression in Spheroids 
 In silico analysis (MatInspector) verified the presence 
of a transcription factor binding site for HIF-1 in the 
TKTL1 promoter (data not shown). To mimic oxygen-
limiting conditions in tumor cell aggregates as found in 
vivo, the three-dimensional spheroid model was applied. 
Upon forming large cellular aggregates with low oxygen 
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 Fig. 1. TKTL1 expression in cell lines.  a mRNA expression of 
TKTL1 relative to β-actin in 11 cell lines. High TKTL1 mRNA ex-
pression was found in monolayers of HT-29 compared to Caco-2, 
T84, SW480, SW837, LoVo, LS 174T, and SW948. No mRNA ex-
pression was found in SW620 and WiDr.  b TKTL1 protein was 
detectable in HT-29 and SW480. Positive control: TKTL1 stable 
transfected HEK293T cells. *p<0.05. 
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supply in the center of the spheroids, malignant cells may 
switch to anaerobic metabolism, i.e. the nonoxidative 
part of the PPP  [4] . As mentioned, hypoxic conditions 
mainly occur in the center of the spheroid structure, es-
pecially in cell lines that form large spheroids  [37] . Spher-
oids of cell lines forming large spheroids subsequently 
also show a trend for necrosis in the center of the cell ag-
gregates.
Spheroids of T84 cells which are relatively small
(online suppl. fig. 1; for all online suppl. material, see 
www.karger.com/doi/10.1159/000355015) weakly ex-
pressed TKTL1 protein over the 5 days of culture 
( fig.  3 a). They did not upregulate HIF-1α protein ex-
pression over time, indicating that there was no signifi-
cant hypoxia ( fig.  3 a, b). In contrast, in spheroids of 
SW480 spheroids which are larger (online suppl. fig. 1) 
HIF-1α protein expression increased over time. This 
was accompanied by an increasing protein expression of 
TKTL1 over time as well as in comparison with spher-
oids of T84 cells ( fig. 3 a, c). 
 HIF-1α protein expression correlated well with TKTL1 
protein expression over 5 days of culture in SW480 spher-
oids, indicating that hypoxia influences the expression of 
TKTL1.
 TKTL1, Glut1 and HkII Expression under Hypoxic 
Conditions 
 To control for the influence of hypoxia on the expres-
sion of TKTL1, we cultured cell lines also in hypoxia in-
cubator chambers for 4 h, 1 and 3 days, respectively, at 
1% O 2 to have more reproducible hypoxic conditions. 
Additionally, cells were kept in medium without glucose 
(and normal content of amino acids) to evaluate the 
 possible changes of TKTL1 expression in the absence of 
glucose. 
 Under normoxic conditions, only minor changes in 
pH were seen between cells cultivated with or without 
glucose ( fig. 4 a, left panel). Induction of hypoxia by ap-
plying 1% O 2 resulted in a decrease in medium pH ( fig. 4 a, 
right panel; 1% O 2 with glucose). This was more pro-
nounced in T84 cells as compared to Caco-2 cells. With-
out glucose, pH was higher, indicating either production 
of alkines or less lactate formation ( fig. 4 a, right panel; 1% 
O 2 without glucose).
 TKTL1 mRNA levels were elevated upon hypoxia in 
T84 and Caco-2, whereas depletion of glucose counter-
acted the effect of hypoxia ( fig. 4 b).
 The expression of genes known to be elevated under 
hypoxia and involved in glucose degradation, Glut1 
( fig. 4 c) and HkII ( fig. 4 d), was highly induced after 1 or 
a b
c d
e f
g h
 Fig. 2. Immunocytochemical staining of CRC cell lines. Cells were 
stained with TKTL1 (red) and DAPI (blue). TKTL1 was expressed 
in the cytoplasm of SW480 ( a ,  b ), HT-29 ( c ,  d ) and T84 ( e ,  f ; all 
magnification ×50 and ×200). Highest expression was seen in HT-
29, followed by SW480, and weaker expression in T84. Staining 
without any antibody ( g ) and staining with secondary antibody ( h ) 
only as negative controls.  
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3 days of cultivation upon hypoxic conditions. Consis-
tent with TKTL1 mRNA levels, the expression of Glut1 
and HkII was reduced in glucose-starved hypoxic cells 
( fig. 4 c, d, right part of graph, without glucose) as com-
pared to hypoxic cells with glucose ( fig. 4 c, d, left part of 
graph).
 In contrast to the mRNA expression, only minor 
changes for TKTL1 protein expression levels were detect-
able during incubation in the hypoxia chamber ( fig. 4 e). 
However, these results have to be interpreted with care as 
upon incubation of cells without glucose and oxygen for 
1 day and 3 days, also β-actin was affected, indicating ne-
crosis and cell death. When cell viability was tested, no 
changes could be observed for all cell lines and conditions 
on day 1. However, on day 3, the cell viability of Caco-2 
cells was strongly reduced upon combination of hypoxia 
and glucose starvation. T84 cells already showed a reduc-
tion in cell viability under hypoxic conditions or glucose 
depletion alone, but the effect was much more pro-
nounced when both conditions were combined (online 
suppl. fig. 2).
 Expression of TKTL1 in Patient Samples 
 TKTL1 protein expression was assessed by Western 
blotting in specimens of 10 patients that had undergone 
surgery due to CRC. The 6 female and 4 male patients 
were 66.5 ± 16.3 years old ( table 1 ). All patients suffered 
from an invasive CRC (TNM classification pT3) except 
2 non-CRC patients with a neuroendocrine carcinoma 
and desmoid tumor. The protein expression of TKTL1 
was heterogeneous among the 8 CRC and 2 control pa-
tients ( fig. 5 a). In 4 of the 8 CRC patients, the TKTL1 
protein expression was higher in tumor as compared 
with corresponding normal tissue ( fig. 5 b). The remain-
ing 4 patients showed lower TKTL1 protein expression 
in tumor as compared with normal tissue. Patients 
G04.89 and G05.274 were excluded from total statistical 
analysis due to weak β-actin expression reflecting deg-
radation processes ( fig. 5 c). However, the difference for 
all remaining 6 patients failed to be statistically signifi-
cant (p = 0.3, Mann-Whitney test). The control patient 
G08.148 who suffered from a neuroendocrine carcino-
ma also had a higher TKTL1 protein expression in tu-
mor as compared with normal tissue. Patient G05.589 
had a slightly higher expression in normal in contrast to 
tumor tissue ( fig.  5 a). No clear trend could be found 
 between the level of TKTL1 expression and clinical pa-
rameters such as tumor grading, status of lymph nodes 
and presence of metastases. TKTL1 expression was fur-
ther assessed in 44 CRC patients by immunohistochem-
istry. The cancer stage was evaluated by the TNM stag-
ing system.
 The patients had moderately differentiated tumors. 
The average age of the patients was 71.3 ± 11.6 years. A 
nuclear as well as a cytoplasmic expression of TKTL1 was 
observed in testis tubuli cells, which served as control 
( fig.  6 a, b). Surrounding stroma cells and Leydig cells 
stained very weak. 
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D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
, R
eg
en
sb
ur
g
13
2.
19
9.
14
5.
19
5 
- 1
0/
10
/2
01
9 
9:
03
:2
2 
AM
 Bentz et al. Digestion 2013;88:182–192
DOI: 10.1159/000355015
188
0
4 h 1 d
+ Glucose
3 d 4 h 1 d 3 d 4 h 1 d 3 d
1
2
6
7
ba
TK
TL
1 
m
RN
A 
no
rm
al
iz
ed
WR
Ǆ
D
FW
LQ
&DFR
T84
&DFR
T84
+ glucose
Normoxia 1% O2
NormoxiaCo
ntr
ol
1% O21% O2
– glucose + glucose – glucose
– Glucose
0
4 h 1 d
+ Glucose
3 d 4 h 1 d 3 d 4 h 1 d 3 d
5
10
15
20
35
40
d
H
KI
I m
RN
A 
no
rm
al
iz
ed
WR
Ǆ
D
FW
LQ
NormoxiaCo
ntr
ol
1% O21% O2
– Glucose
0
4 h 1 d
+ Glucose
3 d 4 h 1 d 3 d 4 h 1 d 3 d
2
1
3
4
7
8
9
c
G
lu
t1
 m
RN
A 
no
rm
al
iz
ed
WR
Ǆ
D
FW
LQ
NormoxiaCo
ntr
ol
1% O21% O2
– Glucose
0
4 h 1 d
+ Glucose
3 d 4 h 1 d 3 d 4 h 1 d 3 d
1
2
3
TK
TL
1 
pr
ot
ei
n 
no
rm
al
iz
ed
WR
Ǆ
D
FW
LQ
Normoxia
N
ot
 d
et
er
m
in
ab
le
N
ot
 d
et
er
m
in
ab
le
Co
ntr
ol
1% O21% O2
– Glucose
e
TKTL1
&D
FR

T8
4
Ǆ$FWLQ
TKTL1
Ǆ$FWLQ
65.4 kDa
42 kDa
65.4 kDa
42 kDa
+ Glucose – Glucose
4 h 1 d 3 d 4 h 1 d 3 d 4 h 1 d 3 d
NormoxiaCo
ntr
ol
1% O2 1% O2
 Fig. 4. TKTL1 expression under hypoxic conditions. Minor chang-
es in medium color under normoxic conditions ( a ), whereas pro-
nounced differences under hypoxia indicated lower pH ( b ). 
TKTL1 expression was induced upon hypoxia on day 3 (with glu-
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 Fig. 6. TKTL1 in patient samples.  a ,  b Nuclear and cytoplasmic 
expression of TKTL1 in tubuli cells of the testis (positive control). 
 c ,  d Staining of TKTL1 in specimens with intraepithelial neoplasia 
as parts of the peripheral border area of a CC ( e–h ) and CC tissues 
and their surrounding tissue (all magnifications ×40–250). The 
immunohistochemical staining of TKTL1 resulted in 14 positive 
and 30 negative samples. 
 Fig. 5. TKTL1 protein expression in tissues from patients with 
CRC. TKTL1 protein expression in tumor tissues (T) and non-
tumor tissues (N) of 8 CRC patients and 2 non-CRC patients.  a All 
expressed TKTL1 protein.  b In 4 of 8 patients, TKTL1 expression 
was upregulated in T compared to N (when normalized to β-actin). 
 c Exclusion of slightly degraded samples. No significant difference 
was found between TKTL1 protein expression in T and N (Mann-
Whitney test, p = 0.3). 
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 TKTL1 positively stained carcinomas are shown in 
 figure 6 c–h. TKTL1 was only expressed in 2 crypts of an 
intraepithelial neoplastic epithelium; the surrounding 
epithelium appeared negative ( fig.  6 d, indicated with
arrows). This is also represented in  figure 6 c. The
non-neoplastic crypt epithelium demonstrated no or 
lower TKTL1 expression. Overall, 31.8% (14) of the sam-
ples were highly TKTL1 positive (IRS  ≥ 4), and 68.2% (30) 
were stained TKTL1 negative (IRS <4).
 Discussion 
 Based on the role of TKTL1 described for other tu-
mors, we investigated its expression in CRC. TKTL1 was 
highly expressed in HT-29 as well as in SW480 cells. Cul-
tivation in the in vitro spheroid model showed that hy-
poxia did influence the expression of TKTL1 and corre-
lated with HIF-1α expression in SW480. TKTL1, Glut1 
and HkII mRNA were reduced in glucose-starved, hyp-
oxic cells compared to hypoxic cells with glucose. Four of 
8 CRC patients had a higher TKTL1 protein expression 
in tumor than in matching normal tissue. Moreover, im-
munohistochemistry demonstrated that 14 CRC patients 
showed increased TKTL1 expression, whereas 30 had no 
detectable TKTL1 expression.
 In contrast to our data, Langbein et al. [34] found 
strong TKTL1 protein expression in CRC which was cor-
related with invasive behavior. They concluded that CRC 
tumorigenesis involves energy production by aerobic gly-
colysis (Warburg effect) in malignant tumors and that 
TKTL1 is a key enzyme specific for glucose metabolism 
in CRC tumor cells and contributes to a malignant phe-
notype  [34, 38] . Interestingly, anaerobic conditions are 
often present in malignant tumors  [39, 40] and may be 
causative for the combined expression of TKTL1 and 
HIF-1α protein in our spheroid model. It is already known 
that hypoxia mostly appears in the center of the spheroid 
structure  [37] . Sun et al. [10] postulated that TKTL1 ex-
pression in head and neck cancer cells contributes to 
 HIF-1α accumulation, and moreover, HIF-1α upregu-
lates glycolytic target genes as well as indirectly increases 
the substrates of TKTL1. HIF-1α inhibits the Krebs cycle 
by upregulating pyruvate dehydrogenase kinase 1 con-
comitant with an inhibition of pyruvate dehydrogenase 
enzyme complex. This leads to an increased conversion 
of pyruvate to lactate even under normoxic conditions in 
cancer cells  [41] .
 It has already been shown that the TKTL1 metabolite 
glyceraldehyde-3-phosphate significantly increases with 
the transformation of benign to malign prostate cancer 
 [42] . These findings are supported by Sun et al.  [10] . They 
could demonstrate that in head and neck cancer cells with 
exogenous TKTL1 overexpression, fructose-6-phosphate 
and glyceraldehyde-3-phosphate were increased and 
consequently an increased aerobic glycolysis, the War-
burg effect, occurred. On the other hand, Xu et al. [12] 
demonstrated by TKTL1 knockdown that a significantly 
reduced glucose consumption and lactate production oc-
curs in HCT116 CC cells.
 A specific upregulation of TKTL1 in a subset of CRCs 
could be demonstrated in our study. 31.8% of the ana-
lyzed tumors had an IRS  ≥ 4, whereas 68.2% of tumor 
samples had an IRS <4.
 As already mentioned, the PPP is controlled by thia-
mine-dependent transketolases  [43] . In 1976, Basu and 
Dickerson [44] claimed an important role of nonoxida-
tive TKT reactions in cancer cell proliferation in patients 
with breast and bronchial carcinoma. Hence, the thia-
mine status of patients with CRC should be considered 
when interpreting the results.
 Conclusion 
 TKTL1 expression in CRC is induced by oxygen-lim-
iting conditions. The role of TKTL1 during tumor pro-
gression in CRC patients and factors that induce TKTL1 
expression have to be further elucidated.
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Erratum
In figure 1c of the article by Amanzada et al. [2012;86:218–227] 
entitled ‘High predictability of a sustained virological response 
(87%) in chronic hepatitis C virus genotype 1 infection treatment 
by combined IL28B genotype analysis and γ-glutamyltransferase/
alanine aminotransferase ratio: a retrospective single-center study’ 
an error occurred. 
Different from what is stated in the Results section on page 222, left 
column, line 9, the text should read: ‘C homozygotes of IL28B with 
low pretreatment γ-GT/ALT ratio showed an OR of 5.5 (95% CI: 
2.2–13.7, p = 0.0001) compared to CT and TT genotypes with low 
γ-GT/ALT ratio. C homozygotes of IL28B with low pretreatment 
γ-GT/ALT ratio showed an OR of 26.6 (95% CI: 10–71.1, p < 0.0001) 
compared to CT and TT genotypes with high (>0.70) pretreatment 
γ-GT/ALT ratio (fig. 1c).’ Figure 1c should read as follows:
87%
(45/52)
CC
57%
(32/56)
CT
ǅ*7$/7UDWLRc
45%

TT

69
5
UD
WH



25&,²S 









34%
(14/41)
CC
21%
(14/67)
CT
ǅ*7$/7UDWLR!
15%
(4/26)
TT
25&,²S
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
, R
eg
en
sb
ur
g
13
2.
19
9.
14
5.
19
5 
- 1
0/
10
/2
01
9 
9:
03
:2
2 
AM
